Healthcare · Nov 17, 2026
Economic Burden of Obesity in Italy
By La Vignera S, Calogero AE
Background/Objectives: Quantify the economic burden of obesity in Italy and explore, through an illustrative scenario-based approach, the potential budgetary implications for the Italian National Health Service (NHS) of full reimbursement of modern Obesity Management Medications (OMMs), including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists. Methods: Narrative review based on literature searches of PubMed/MEDLINE, Scopus, and Google Scholar from inception to September 2026 and covering the epidemiology and economic burden of obesity in Italy, the current AIFA reimbursement landscape, cost-effectiveness evidence for approved OMMs, and international reimbursement models. Evidence synthesized from cost-of-illness studies, clinical trials, health technology assessments, and economic modeling. Results: Obesity imposes an estimated €13 billion annual burden on Italy (direct costs €7.89 billion; indirect costs €5.45 billion). AIFA currently restricts reimbursement primarily to patients with obesity plus type 2 diabetes mellitus (T2DM) via Nota 13, excluding the majority of individuals with obesity. Modern pharmacotherapies, including semaglutide 2.4 mg and tirzepatide, achieve 12–22% weight reduction with favorable cost-effectiveness ratios in several non-Italian economic evaluations, whereas Italian-specific analyses are lacking. In an illustrative scenario-based estimate derived from indirect modelling assumptions (not a validated decision-analytic, budget-impact, or cost-effectiveness model, and without formal sensitivity analysis), full reimbursement could avoid approximately €2–4 billion in obesity-related healthcare costs over 10 years (gross avoided costs; medication expenditure was not netted off and net savings were not demonstrated) through prevention of T2DM, cardiovascular disease (CVD), obstructive sleep apnea (OSA), and other obesity-related comorbidities. Conclusions: Full reimbursement of evidence-based Obesity Management Medications (OMMs) may offer long-term value for the Italian NHS, although reimbursement decisions require dedicated Italian cost-effectiveness and budget-impact analyses. Policy priorities should include expanding AIFA Nota 13 criteria, implementing outcomes-based risk-sharing agreements, and formally recognizing obesity as a chronic disease in Italian health policy.
doi.org/10.3390/healthcare14223942Open accessIndustry & policy